Technology | March 20, 2014

FDA Approves Piramal Imaging's PET Imaging Tracer for Beta-Amyloid Plaques

Approval expands availability of Alzheimer's diagnostic imaging agent

Neuraceq, florbetaben, F18, F-18, Piramal, alzheimer's

A comparison of brain images showing positive and negative scans for the presence of beta-amyloid plaques using the Neuraceq (florbetaben F-18) radiotracer.

Neuraceq, florbetaben, F18, F-18, Piramal, alzheimer's

March 20, 2014 — The U.S. Food and Drug Administration (FDA) approved a third beta-amyloid plaque positron emission tomography (PET) imaging radiotracer to identify Alzheimer’s disease. The FDA’s approval of Piramal Imaging’s Neuraceq (florbetaben F-18 injection) comes four weeks after receiving marketing authorization in Europe. 

It is the third radiotracer to gain FDA clearance for beta amyloid plaque imaging. Last October, the FDA-cleared Vizamyl (flutemetamol F-18 injection) was developed for GE Healthcare by Medi-Physics Inc. The first agent to gain approval was Amyvid (florbetapir F-18 Injection) in April 2012. Amyvid was developed by Eli Lilly & Co. and Avid Radiopharmaceuticals Inc. Prior to these agents, the only clear diagnosis of Alzheimer’s was by post-mortem autopsy. 
 
Neuraceq is indicated for PET imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline.
 
There are an estimated 7.7 million new cases of dementia each year worldwide.[1] Alzheimer's disease accounts for 60-80 percent of all dementia diagnoses.[2] However, a clinical diagnosis of probable AD is incorrect upon post-mortem histological investigation in 10-30 percent of cases.[3]
 
The Centers for Medicare and Medicaid Services (CMS) declared it will cover a beta-amyloid PET scan for patients under Coverage with Evidence Development (CED) programs. The objective of these programs is to assess the impact of beta-amyloid scans on improving patient outcomes or advancing patient treatment options.
 
"Alzheimer's disease or any form of cognitive impairment is a daunting diagnosis," said Ludger Dinkelborg, director of the board, Piramal Imaging. "For the patients and caregivers, the concern centers around understanding what the future holds. For physicians, the challenge is properly assessing the patient and determining the best care path."
 
"The FDA's approval of Neuraceq is a significant milestone for Piramal Imaging and demonstrates our dedication to advancing innovation in molecular imaging globally," said Swati Piramal, vice chairperson, Piramal Enterprises Ltd. "The rising prevalence of Alzheimer's disease and cognitive impairment is being felt individually and collectively around the world. Our goal as a company is to usher in a new era of imaging that helps paint clearer pictures of the physiology of such conditions and helps improve patient outcomes."
 
The FDA approval of Neuraceq is based on safety data from 872 patients who participated in global clinical trials as well as three studies that examined images from adults with a range of cognitive function, including 205 end-of-life patients who had agreed to participate in a post-mortem brain donation program. Images were analyzed from 82 subjects with post-mortem confirmation of the presence or absence of beta-amyloid neuritic plaques. Correlation of the visual PET interpretation with histopathology in these 82 brains demonstrated that Neuraceq accurately detects moderate to frequent beta-amyloid neuritic plaques in the brain and is a useful tool to estimate the density of these plaques in life.
 
Piramal Imaging has partnered with IBA Molecular for manufacturing and distribution of Neuraceq. IBA Molecular owns and operates a network of 49 PET isotope facilities worldwide, a network that is unique in both size and scope.
 
Neuraceq Indications and Use
A negative Neuraceq scan indicates sparse to no amyloid neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition.
 
Neuraceq is an adjunct to other diagnostic evaluations.
 
The FDA limits established for this radiotracer include that a positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder. Also, the safety and effectiveness of Neuraceq have not been established for predicting development of dementia or other neurologic conditions or for monitoring responses to therapies.
 
In clinical trials, the most frequently observed adverse drug reactions in 872 subjects with 978 Neuraceq administrations were injection/application site erythema (1.7%), injection site irritation (1.2%) and injection site pain (3.9%).
 
For more information: www.piramal.com/imaging
 
References:
1. WHO. Dementia: A public health priority; 2012
?2. Alzheimer's Association. Alzheimer Dement. 2013;9 ?
3. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. 2007. http://psychiatryonline.org/content.aspx?bookid=28&sectionid=1679489#152139 (accessed20 Dec 2011)
 

Related Content

ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
CorTechs Labs Receives FDA 510(k) Clearance for NeuroQuant for Quantitative Brain MRI Analysis
Technology | Magnetic Resonance Imaging (MRI) | September 29, 2017
CorTechs Labs announced that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for...
Brain Disconnections May Contribute to Parkinson's Hallucinations
News | Neuro Imaging | September 27, 2017
Researchers have found that disconnections of brain areas involved in attention and visual processing may contribute to...
Toshiba Showcases MRI Workflow Enhancements at RSNA 2017
News | Magnetic Resonance Imaging (MRI) | September 21, 2017
September 21, 2017 — Toshiba Medical will highlight its latest...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Overlay Init